Andrew Dudum Sells 100,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 100,000 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company’s stock, valued at $983,271.96. The trade was a 78.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Trading Up 0.6 %

NYSE HIMS opened at $42.12 on Thursday. The stock has a market cap of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35. Hims & Hers Health, Inc. has a 12 month low of $8.58 and a 12 month high of $44.43. The company’s 50-day moving average price is $29.82 and its 200-day moving average price is $23.00.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HIMS. Canaccord Genuity Group raised their price target on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Piper Sandler raised their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $25.13.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC increased its position in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the period. US Bancorp DE raised its holdings in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after purchasing an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $48,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.